Cargando…

Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells

Enhanced rRNA synthesis is a downstream effect of many of the signaling pathways that are aberrantly activated in cancer, such as the PI3K/mTOR and MAP kinase pathways. Recently, two new rRNA synthesis inhibitors have demonstrated therapeutic effects on cancer cells while sparing normal cells. One o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Negi, Sandeep S., Brown, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741494/ https://www.ncbi.nlm.nih.gov/pubmed/26472108

Ejemplares similares

rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis
por: Negi, Sandeep S., et al.
Publicado: (2015)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
por: Cornelison, Robert, et al.
Publicado: (2021)

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma
por: Kang, Chang-Won, et al.
Publicado: (2022)

A transcriptional program associated with cell cycle regulation predominates in the anti-inflammatory effects of CX-5461 in macrophage
por: Wang, Jie, et al.
Publicado: (2022)

Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461
por: Li, Guihong, et al.
Publicado: (2018)

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
por: Xuan, Jiachen, et al.
Publicado: (2020)

Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461
por: Masud, Tehmina, et al.
Publicado: (2021)

CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I
por: Lehman, Stacey L., et al.
Publicado: (2022)

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
por: Xu, Hong, et al.
Publicado: (2017)

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
por: Quin, Jaclyn, et al.
Publicado: (2016)

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
por: Sanij, Elaine, et al.
Publicado: (2020)

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
por: Pan, Min, et al.
Publicado: (2021)

CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma
por: Li, Leiming, et al.
Publicado: (2016)

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
por: Son, Jinbae, et al.
Publicado: (2020)

The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers
por: Ismael, Mohammed, et al.
Publicado: (2019)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling
por: Xu, Xia, et al.
Publicado: (2021)

CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response
por: Snyers, Luc, et al.
Publicado: (2022)

The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
por: Mars, Jean-Clément, et al.
Publicado: (2020)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
por: Hilton, John, et al.
Publicado: (2022)

SB225002 Induces Cell Death and Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells through the Activation of GLIPR1
por: de Vasconcellos, Jaíra Ferreira, et al.
Publicado: (2015)

Sulforaphane Induces Cell Cycle Arrest and Apoptosis in Acute Lymphoblastic Leukemia Cells
por: Suppipat, Koramit, et al.
Publicado: (2012)

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer
por: Chung, Shin-Yi, et al.
Publicado: (2022)

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
por: Yan, Shunfei, et al.
Publicado: (2020)

Cx25 contributes to leukemia cell communication and chemosensitivity
por: Sinyuk, Maksim, et al.
Publicado: (2015)

CD47-ligation induced cell death in T-acute lymphoblastic leukemia
por: Leclair, Pascal, et al.
Publicado: (2018)

A murine model for human early/immature T-cell precursor acute lymphoblastic leukemia (EITP ALL)
por: Negi, Vijay, et al.
Publicado: (2022)

Transient bone marrow hypoplasia preceding T-Cell acute lymphoblastic leukemia: a case report
por: Naturinda, Ernest, et al.
Publicado: (2021)

Inhibition of DEK Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia Cells
por: Tian, Xiaoxue, et al.
Publicado: (2022)

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia
por: Johansson, Kimberly B., et al.
Publicado: (2023)

3,3′-Diindolylmethane Induces G(1) Arrest and Apoptosis in Human Acute T-Cell Lymphoblastic Leukemia Cells
por: Shorey, Lyndsey E., et al.
Publicado: (2012)

Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia
por: Tan, Shi Hao, et al.
Publicado: (2017)

Transient Responses to NOTCH and TLX1/HOX11 Inhibition in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
por: Rakowski, Lesley A., et al.
Publicado: (2011)

Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
por: Westcott, Peter M. K., et al.
Publicado: (2023)

Increased expression of CX43 on stromal cells promotes leukemia apoptosis
por: Yang, Shijie, et al.
Publicado: (2015)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

Inhibition of peptidoglycan synthesis is sufficient for total arrest of staphylococcal cell division
por: Puls, Jan-Samuel, et al.
Publicado: (2023)

Inflammatory signals are sufficient to elicit TOX expression in mouse and human CD8(+) T cells
por: Maurice, Nicholas J., et al.
Publicado: (2021)

Prostaglandin production selectively in brain endothelial cells is both necessary and sufficient for eliciting fever
por: Shionoya, Kiseko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1gl30p1vu0hbssme9gj5eqhap5